255 filings
Page 4 of 13
8-K
ptsaq3
11 May 21
Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:17pm
8-K
nsx2vcf0m
12 Mar 21
Departure of Directors or Certain Officers
5:03pm
424B5
ymiphdurq9z dj8arnhg
10 Mar 21
Prospectus supplement for primary offering
5:26pm
8-K
9a54n ab7
10 Mar 21
Other Events
5:24pm
424B5
gwkx003x
9 Mar 21
Prospectus supplement for primary offering
5:26pm
8-K
im0361qlu9mya8h2t65e
1 Mar 21
Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update
4:04pm
8-K/A
bynwmr z5x
14 Jan 21
Departure of Directors or Certain Officers
8:09am
8-K
05csoc fi
14 Jan 21
Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021
8:05am
8-K
f062o218
5 Nov 20
Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:11pm
CT ORDER
fths3kgiav8u1 kh88
1 Sep 20
Confidential treatment order
9:33am
8-K
dz188fjb9idkbccmq
17 Aug 20
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer
8:34am
424B5
ynuq 8vmo52s16man9x
6 Aug 20
Prospectus supplement for primary offering
5:17pm
8-K
fgk5d 2asvia
6 Aug 20
Entry into a Material Definitive Agreement
4:56pm
8-K
055umz3c
6 Aug 20
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
4:14pm
EFFECT
gxlg8u7o3fh7gj6
15 Jun 20
Notice of effectiveness
12:16am